4 results about "Acyl coenzyme A" patented technology

The invention belongs to the technical field of biology, and discloses butyryl coenzyme A: acetic acid coenzyme A transferase from the bottom of a white wine cellar and application of the butyryl coenzyme A: acetic acid coenzyme A transferase. A gene nucleotide sequence of the butyryl coenzyme A: acetic acid coenzyme A transferase is shown as SEQ ID NO.2, and the overall length of the sequence is 657 bp; the amino acid sequence of the encoded protein is as shown in SEQ ID NO.1, and 218 amino acid residues are encoded. According to the butyryl coenzyme A: acetic acid coenzyme A transferase explored for the first time, biosynthesis of butyric acid and hexanoic acid can be remarkably promoted, and a novel functional enzyme is provided for efficient synthesis of medium and short chain fatty acid, acyl coenzyme A and acyl ester. When the enzyme is applied to Saccharomyces cerevisiae, the synthesis capability of butyric acid and hexanoic acid is remarkably improved, the enzyme has outstanding economic value and industrial application prospect, and meanwhile, the resource reserve is broadened for mining and industrial application of novel functional enzymes.

The invention discloses a microorganism capable of improving the production level of p-coumaric acid or p-coumaric acid derivatives as well as a construction method and application of the microorganism. The construction method comprises the following steps: transforming genetic targets related to metabolic pathways of p-coumaric acid of the microorganism; the target spot is one or a combination of two or more of 4-coumaroyl coenzyme A ligase, hydroxycinnamyl coenzyme A hydratase lyase, hydroxyacyl coenzyme A dehydrogenase, beta-keto-acyl coenzyme A thiolated enzyme and 3-(aryl) acrylate reductase, and is transformed to remove part or all of the activity of genetic target spots related to a coumaric acid metabolic pathway. Genetic targets related to metabolic pathways of p-coumaric acid are modified, so that the degree of degrading p-coumaric acid by microorganisms is reduced, and the yield and / or production efficiency of p-coumaric acid and p-coumaric acid derivatives produced by the microorganisms are / is improved.

The present application relates to a kind of double bond reductase LbDBR2 and its application, the amino acid sequence of the double bond reductase LbDBR2 is as shown in SEQ ID NO:1.The present application first finds double bond reductase LbDBR2 from medlar, it can efficiently respectively with coffee acyl coenzyme A, p-coumaroyl coenzyme A and feruloyl coenzyme A such as phenylpropionyl coenzyme A catalytic synthesis corresponding dihydrophenylpropionyl coenzyme A, provides new biosynthesis path for dihydrophenylpropionyl coenzyme A.

The invention belongs to the technical field of biological medicines, particularly relates to the technical direction of cooperation of medical oncology treatment and immunotherapy, and provides application of crotonic acid and / or crotonyl-coenzyme A in preparation of medicines for treating tumors. It is confirmed for the first time that crotonic acid can inhibit proliferation and migration of various solid tumor cells including breast cancer, liver cancer and colorectal cancer, the inhibition effect of crotonyl coenzyme A on breast cancer metastasis is defined, the research blank of crotonyl coenzyme A and crotonyl coenzyme A in the field of tumor treatment is filled, and short-chain fatty acid and short-chain fatty-acyl coenzyme A anti-tumor substance libraries are enriched. Meanwhile, it is proved that crotonic acid can up-regulate expression of tumor tissue PD-L1, when the crotonic acid is combined with the PD-L1 monoclonal antibody, the cancer suppression effect is remarkably better than that of independent medication, the immunotherapy effect is improved, the applicable crowd is expanded, and a novel treatment substance with a broad-spectrum cancer suppression effect and a synergistic treatment strategy are provided.